802
Views
28
CrossRef citations to date
0
Altmetric
Psoriasis and atopic dermatitis

Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab

ORCID Icon, , & ORCID Icon
Pages 40-44 | Received 11 Feb 2018, Accepted 30 Mar 2018, Published online: 03 May 2018

References

  • Talamonti M, Galluzzo M, Servoli S, et al. Alexithymia and plaque psoriasis: preliminary investigation in a clinical sample of 250 patients. Dermatology. 2016;232:648–654.
  • Bobotsis R, Gulliver WP, Monaghan K, et al. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol. 2016;175:464–472.
  • Murase JE, Chan KK, Garite TJ, et al. Hormonal effect on psoriasis in pregnancy and postpartum. Arch Dermatol. 2005;141:601–606.
  • Bogas M, Leandro MJ. Biologic therapy and pregnancy. A systematic literature review. Acta Reumatol Port. 2011;36:219–232.
  • Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor alpha medications in pregnancy. Birth Defects Res A Clin Mol Teratol. 2012;94:607–611.
  • Chaudrey KH, Kane SV. Safety of immunomodulators and anti-TNF therapy in pregnancy. Curr Treat Options Gastroenterol. 2015;13:77–89.
  • Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: a patient series. Dermatol Ther. 2017;30. doi:10.1111/dth.12454
  • Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80:727–739.
  • Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review. Actas Dermosifiliogr. 2014;105:734–743.
  • Androulakis I, Zavos C, Christopoulos P, et al. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. WJG. 2015;21:13205–13211.
  • Fujikawa K, Endo Y, Mizokami A, et al. Successful treatment with adalimumab for intestinal Behcet’s disease during pregnancy. Intern Med. 2016;55:1375–1378.
  • Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol. 2012;11:1240–1241.
  • Martin PL, Sachs C, Imai N, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23 p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89:351–363.
  • Fotiadou C, Lazaridou E, Sotiriou E, et al. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep. 2012;6:105–107.
  • Venturin C, Nancey S, Danion P, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol. 2017;17:80.
  • Cortes X, Borrás-Blasco J, Antequera B, et al. Ustekinumab therapy for Crohn’s disease during pregnancy: a case report and review of the literature. J Clin Pharm Ther. 2017;42:234–236.
  • Rowan CR, Cullen G, Mulcahy HE, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks gestation. J Crohns Colitis. 2018;12:376–378.
  • Galli-Novak E, Mook SC, Büning J, et al. Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn’s disease and paradoxical psoriasis. J Eur Acad Dermatol Venereol. 2016;30:e191–e192.
  • Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017;3:21–25.
  • Pregnancy and lactation labeling (drugs) final rule. 2014 [cited 2017 December]. Available from: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm
  • Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy. Drug Saf. 2000;23:245–253.
  • Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann Pharmacother. 2000;35:1485–1489.
  • Doering PL, Boothby LA, Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? Am J Obstet Gynecol. 2002;187:333–339.
  • Sheeran C, Nicolopoulos J. Pregnancy outcomes of two patients exposed to ustekinumab in the first trimester. Australas J Dermatol. 2014;55:235–236.
  • Alsenaid A, Prinz JC. Inadvertent pregnancy during ustekinumab therapy in a patient with plaque psoriasis and impetigo herpetiformis. J Eur Acad Dermatol Venereol. 2016;30:448–489.
  • Rocha K, Piccinin MC, Kalache LF. Pregnancy during ustekinumab treatment for severe psoriasis. Dermatology. 2015;231:103–104.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.